RXi forms microRNA research agreements with miRagen, Mirna

04/13/2010 | Mass High Tech (Boston)

RXi Pharmaceuticals agreed to collaborate with miRagen Therapeutics, which develops microRNA-based drugs for cardiovascular and muscular disorders, to discover pharmaceutical targets using microRNA technology. The company also will work with Mirna Therapeutics, a Texas company that focuses on early-stage drugs for cancer.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
In house Compliance Officer
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC